As noted in the Methods, sensitivity was calculated in two ways: firstly for detecting homozygous SMN1 deletions (which were the target of screening), and secondly for detecting any SMA case (including compound heterozygotes which could not be identified via screening). The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.